Could simply thinking about exercise – without so much as lifting a finger – really do the trick?
It sounds incredibly unlikely, but ‘motor imagery’ is a technique often used by top athletes, and some studies suggest that you can use it to improve your strength by mental training alone.
Trust Me, I’m a Doctor teamed up with The University of Northampton’s Professor Tony Kay to put this wonderfully weird idea to the test Read on
Scientists have discovered never-before-seen vessels in the brain
Scientists in the US have discovered a new series of lymphatic vessels in the body that link the brain to the immune system – a connection researchers had previously thought didn’t exist.
The discovery could not only prompt a rewrite of the textbooks, it might also lead to a new understanding of how our immune system influences our brain and our behaviour. Read on.
Oxford Branch Newsletter MS Society
MEPC cake sale
CAKES NEEDED THIS FRIDAY!
New report calls for neurology care to be delivered closer to home

The Thames Valley Strategic Clinical Network launches a new report (link is external) calling for improvements in neurological services provided in the community.
The report slams the current provision of care for people with long-term neurological conditions, describing it as unsatisfactory from all perspectives, including those of patients, carers and commissioners (the people who plan and buy services). It draws a picture of care that is centred around institutions rather than patients, and cautions that this lack of integrated care results in delayed access to expert advice, particularly in times of crisis. Read on.
Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%
Biogen and AbbVie have been granted EU marketing authorization forZinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Read on.
Siponimod Effective in Reducing Disease Activity in Relapsing=-Remitting MS
Results from the 24-month extension of the phase 2 BOLD study demonstrated no new safety concerns and low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated with siponimod. Read on.
Could the gut microbiome be a new therapeutic target for multiple sclerosis?
New Rochelle, NY, July 6, 2016–An increasing number of clinical studies are pointing to a link between the autoimmune disease multiple sclerosis (MS) and the composition of microbes in the human gut, sparking new research on the gut microbiome as a potential target for MS treatment and prevention. Read on